{"title":"177Lu-DOTATATE在放射性核素治疗神经内分泌肿瘤中的辐射吸收剂量效应：病人与模拟的混合研究。","authors":"Alireza Seyedabadi, Pejman Porouhan, Hamid-Reza Sadoughi, Ruhollah Ghahramani-Asl","doi":"10.1093/rpd/ncaf054","DOIUrl":null,"url":null,"abstract":"<p><p>Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs). This study aims to assess the radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of NETs. Four patients were selected for imaging using 177Lu-octreotide or DOTATATE via Single photon emission computed tomography/Computed tomography (SPECT/CT). The absorbed doses were calculated employing the Medical Internal Radiation Dose (MIRD) method and S-value tables associated with 177Lu, utilizing the GEANT4 Application for Tomographic Emission (GATE) calculation code. The mean percentage differences in the S-values between the GATE and IDAC2.1 calculation methods were -0.7 for S (Spleen→Spleen), -3.5 for S (Kidneys→Kidneys), and 4.9 for S (Liver→Liver). The mean absorbed doses from the GATE were 0.076, 0.20, 0.29, and 0.47 mGy/MBq for the liver, kidneys, spleen, and tumors, respectively. Assessment of the results obtained from the GATE code as a voxel-level dose calculation tool in non-uniform media showed that 177Lu-DOTATATE may provide beneficial therapeutic effects.</p>","PeriodicalId":20795,"journal":{"name":"Radiation protection dosimetry","volume":" ","pages":"602-611"},"PeriodicalIF":0.7000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation.\",\"authors\":\"Alireza Seyedabadi, Pejman Porouhan, Hamid-Reza Sadoughi, Ruhollah Ghahramani-Asl\",\"doi\":\"10.1093/rpd/ncaf054\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs). This study aims to assess the radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of NETs. Four patients were selected for imaging using 177Lu-octreotide or DOTATATE via Single photon emission computed tomography/Computed tomography (SPECT/CT). The absorbed doses were calculated employing the Medical Internal Radiation Dose (MIRD) method and S-value tables associated with 177Lu, utilizing the GEANT4 Application for Tomographic Emission (GATE) calculation code. The mean percentage differences in the S-values between the GATE and IDAC2.1 calculation methods were -0.7 for S (Spleen→Spleen), -3.5 for S (Kidneys→Kidneys), and 4.9 for S (Liver→Liver). The mean absorbed doses from the GATE were 0.076, 0.20, 0.29, and 0.47 mGy/MBq for the liver, kidneys, spleen, and tumors, respectively. Assessment of the results obtained from the GATE code as a voxel-level dose calculation tool in non-uniform media showed that 177Lu-DOTATATE may provide beneficial therapeutic effects.</p>\",\"PeriodicalId\":20795,\"journal\":{\"name\":\"Radiation protection dosimetry\",\"volume\":\" \",\"pages\":\"602-611\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation protection dosimetry\",\"FirstCategoryId\":\"93\",\"ListUrlMain\":\"https://doi.org/10.1093/rpd/ncaf054\",\"RegionNum\":4,\"RegionCategory\":\"环境科学与生态学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ENVIRONMENTAL SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation protection dosimetry","FirstCategoryId":"93","ListUrlMain":"https://doi.org/10.1093/rpd/ncaf054","RegionNum":4,"RegionCategory":"环境科学与生态学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENVIRONMENTAL SCIENCES","Score":null,"Total":0}
Radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of neuroendocrine tumors: a hybrid study of patient and simulation.
Recent developments in targeted radiopharmaceuticals offer promising options for diagnosis and treatment by specifically targeting the overexpressed somatostatin receptors in neuroendocrine tumors (NETs). This study aims to assess the radiation absorbed dose efficacy of 177Lu-DOTATATE in radionuclide therapy of NETs. Four patients were selected for imaging using 177Lu-octreotide or DOTATATE via Single photon emission computed tomography/Computed tomography (SPECT/CT). The absorbed doses were calculated employing the Medical Internal Radiation Dose (MIRD) method and S-value tables associated with 177Lu, utilizing the GEANT4 Application for Tomographic Emission (GATE) calculation code. The mean percentage differences in the S-values between the GATE and IDAC2.1 calculation methods were -0.7 for S (Spleen→Spleen), -3.5 for S (Kidneys→Kidneys), and 4.9 for S (Liver→Liver). The mean absorbed doses from the GATE were 0.076, 0.20, 0.29, and 0.47 mGy/MBq for the liver, kidneys, spleen, and tumors, respectively. Assessment of the results obtained from the GATE code as a voxel-level dose calculation tool in non-uniform media showed that 177Lu-DOTATATE may provide beneficial therapeutic effects.
期刊介绍：
Radiation Protection Dosimetry covers all aspects of personal and environmental dosimetry and monitoring, for both ionising and non-ionising radiations. This includes biological aspects, physical concepts, biophysical dosimetry, external and internal personal dosimetry and monitoring, environmental and workplace monitoring, accident dosimetry, and dosimetry related to the protection of patients. Particular emphasis is placed on papers covering the fundamentals of dosimetry; units, radiation quantities and conversion factors. Papers covering archaeological dating are included only if the fundamental measurement method or technique, such as thermoluminescence, has direct application to personal dosimetry measurements. Papers covering the dosimetric aspects of radon or other naturally occurring radioactive materials and low level radiation are included. Animal experiments and ecological sample measurements are not included unless there is a significant relevant content reason.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
